Holen Sie sich die Stockscreener-App
4.31
1.60%
-0.07
Handel nachbörslich:
4.31
Schlusskurs vom Vortag:
$4.38
Offen:
$4.35
24-Stunden-Volumen:
206.71K
Relative Volume:
0.29
Marktkapitalisierung:
$279.60M
Einnahmen:
$207.32M
Nettoeinkommen (Verlust:
$-61.04M
KGV:
-4.5004
EPS:
-0.9577
Netto-Cashflow:
$-25.97M
1W Leistung:
+7.75%
1M Leistung:
+8.29%
6M Leistung:
+85.78%
1J Leistung:
-19.81%
1-Tages-Spanne:
$4.131
$4.45
1-Wochen-Bereich:
$3.94
$4.45
52-Wochen-Spanne:
$1.17
$7.78
Treace Medical Concepts Inc Stock (TMCI) Company Profile
Firmenname
Treace Medical Concepts Inc
Sektor
Branche
Telefon
(904) 373-5940
Adresse
100 PALMETTO PARK PLACE, PONTE VEDRA
Compare TMCI vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TMCI
Treace Medical Concepts Inc
|
4.31 | 264.68M | 207.32M | -61.04M | -25.97M | -0.9577 |
ABT
Abbott Laboratories
|
105.74 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
325.74 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
85.40 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
46.73 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.03 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
Treace Medical Concepts Inc Stock (TMCI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-07 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-11-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-02-04 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-12-31 | Eingeleitet | Lake Street | Buy |
| 2024-12-17 | Fortgesetzt | JP Morgan | Neutral |
| 2024-05-16 | Herabstufung | UBS | Buy → Neutral |
| 2024-05-08 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-05-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-05-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-05-08 | Herabstufung | Stifel | Buy → Hold |
| 2024-05-08 | Herabstufung | Truist | Buy → Hold |
| 2023-09-29 | Eingeleitet | UBS | Buy |
| 2023-05-01 | Eingeleitet | Truist | Buy |
| 2023-04-11 | Eingeleitet | Stephens | Equal-Weight |
| 2022-05-12 | Eingeleitet | BTIG Research | Buy |
| 2022-01-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-05-18 | Eingeleitet | JP Morgan | Overweight |
| 2021-05-18 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-05-18 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-18 | Eingeleitet | Stifel | Buy |
Alle ansehen
Treace Medical Concepts Inc Aktie (TMCI) Neueste Nachrichten
Treace Medical Concepts Inc (TMCI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TMCI|Treace Medical Concepts Inc|Price:4.060|Chg%:+0.060 - TradingKey
Treace Medical Concepts Inc (TMCI) Cash Flow - TradingKey
Treace Medical Concepts Inc - TradingKey
Treace Medical Concepts Inc (TMCI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Treace Medical Concepts, Inc. Revenue Breakdown – NASDAQ:TMCI - TradingView
Investors urged to act as law firm probes Treace Medical's board for possible breaches of duty. - Pluang
Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire
Treace to Report Second Quarter 2026 Financial Results on August 7, 2026 - The Manila Times
Treace will discuss Q2 results live before markets open Aug. 7 - Stock Titan
TMCI|Treace Medical Concepts Inc|Price:4.000|Chg%:-0.050 - TradingKey
Treace Medical Concepts to Release Q2 2026 Financial Results - Intellectia AI
Treace Medical Concepts Lawsuit: Court Dismisses Investor Complaint Without Prejudice - TipRanks
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Receives Consensus Recommendation of "Reduce" from Brokerages - MarketBeat
Treace Medical Concepts (NASDAQ:TMCI) Given New $4.00 Price Target at Truist Financial - MarketBeat
Treace Medical Concepts Price Target Raised to $4.00/Share From $2.00 by Truist Securities - Moomoo
Truist Securities Adjusts Price Target on Treace Medical Concepts to $4 From $2, Maintains Hold Rating - marketscreener.com
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Short Interest Down 46.6% in June - MarketBeat
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Treace Medical Concepts, Inc. (TMCI) - Supply Chain Digital
Law firm investigates Treace Medical for alleged false statements affecting shareholders. - Pluang
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
3 Penny Stocks With Market Caps Under $900M To Watch - simplywall.st
TMCITreace Medical Concepts Inc Earnings - Finviz
Treace Medical Concepts, Inc.(NasdaqGS:TMCI) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Treace Medical Concepts, Inc.(NasdaqGS:TMCI) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Treace Medical Concepts, Inc.(NasdaqGS: TMCI) dropped from Russell 2000 Index - marketscreener.com
Treace Medical Concepts, Inc.(NasdaqGS:TMCI) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Treace Medical Concepts, Inc.(NasdaqGS:TMCI) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Treace Medical Concepts, Inc.(NasdaqGS: TMCI) added to Russell Microcap Index - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Treace Medica - The National Law Review
Treace Medical Concepts, Inc. (TMCI) Investigation: Bronstein, Ge - The National Law Review
Treace Medical Concepts, Inc.(NasdaqGS: TMCI) dropped from Russell 3000 Index - marketscreener.com
Levi & Korsinsky Notifies Treace Medical Concepts, Inc. (TMCI) InvestorsLead Plaintiff Deadline on June 10, 2025 - The National Law Review
Treace Medical Concepts Inc (TMCI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Analysts Are Updating Their Treace Medical Concepts, Inc. (NASDAQ:TMCI) Estimates After Its First-Quarter Results - 富途牛牛
Enterprise value to revenue forward of Treace Medical Concepts, Inc. – NASDAQ:TMCI - TradingView
Price to earnings forward of Treace Medical Concepts, Inc. – NASDAQ:TMCI - TradingView
Price to earnings forward of Treace Medical Concepts, Inc. – BOATS:TMCI - TradingView
Price to sales forward of Treace Medical Concepts, Inc. – NASDAQ:TMCI - TradingView
Enterprise value to EBITDA forward of Treace Medical Concepts, Inc. – NASDAQ:TMCI - TradingView
Enterprise value to EBITDA forward of Treace Medical Concepts, Inc. – BOATS:TMCI - TradingView
Treace Medical Concepts Inc (TMCI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Treace Medical Concepts (TMCI) Q3 2024 earnings summary - Quartr
Treace Medical Concepts (TMCI) Q2 2024 earnings summary - Quartr
Treace Medical Concepts (TMCI) Q1 2026 earnings summary - Quartr
Treace Medical Concepts (TMCI) Proxy filing Summary - Quartr
Treace Medical Concepts (TMCI) Sidoti Small-Cap Virtual Investor Conference Summary - Quartr
Treace Announces First Surgical Case with the HyperPlate™ XM Dynamic Compression Locking Implant System - GlobeNewswire
Treace Medical Concepts Inc (TMCI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Treace Medical Concepts Inc (TMCI) Institutional Confidence - TradingKey
Finanzdaten der Treace Medical Concepts Inc-Aktie (TMCI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Treace Medical Concepts Inc-Aktie (TMCI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Treace John T. | Chief Executive Officer |
Jun 11 '26 |
Buy |
4.04 |
22,887 |
92,541 |
7,376,150 |
| Treace John T. | Chief Executive Officer |
Jun 01 '26 |
Buy |
3.56 |
50,000 |
177,915 |
7,323,833 |
| Treace John T. | Chief Executive Officer |
May 28 '26 |
Buy |
3.02 |
61,202 |
184,824 |
7,273,833 |
| Treace John T. | Chief Executive Officer |
May 27 '26 |
Buy |
2.87 |
49,810 |
143,189 |
7,212,631 |
| Treace John T. | Chief Executive Officer |
May 26 '26 |
Buy |
2.79 |
4,508 |
12,576 |
7,162,821 |
| Treace John T. | Chief Executive Officer |
May 14 '26 |
Buy |
2.62 |
61,750 |
161,495 |
7,158,313 |
| Treace John T. | Chief Executive Officer |
May 13 '26 |
Buy |
2.46 |
49,013 |
120,533 |
7,096,563 |
| Treace John T. | Chief Executive Officer |
May 12 '26 |
Buy |
2.17 |
43,000 |
93,478 |
7,047,550 |
| Scanlan Sean F. | Chief Innovation Officer |
Feb 10 '26 |
Option Exercise |
1.05 |
16,875 |
17,719 |
706,474 |
| Scanlan Sean F. | Chief Innovation Officer |
Jan 21 '26 |
Option Exercise |
0.72 |
53,500 |
38,520 |
427,099 |
1.04%
11.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):